<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15880">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900157</url>
  </required_header>
  <id_info>
    <org_study_id>D4190C00055</org_study_id>
    <nct_id>NCT02900157</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK,
      immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid
      tumors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 9, 2016</start_date>
  <completion_date type="Anticipated">January 9, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects reporting infusion related reactions</measure>
    <time_frame>First dose of study medication through 30 days after the first dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects that develop changes in detectable antidrug antibodies to MEDI9090</measure>
    <time_frame>First dose of study medication through 6 months after the last dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual MEDI9090 concentrations</measure>
    <time_frame>First dose of study medication through 3 months after the last dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting adverse events</measure>
    <time_frame>Screening through 3 months after last dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects reporting serious adverse events</measure>
    <time_frame>Screening through 3 months after the last dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with vital sign abnormalities reported as adverse events</measure>
    <time_frame>Screening through 3 months after the last dose of study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with ECG abnormalities reported as adverse events</measure>
    <time_frame>Screening through 3 months after the last dose of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MEDI9090</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI9090</intervention_name>
    <description>MEDI9090 will be administered by IV infusion</description>
    <arm_group_label>MEDI9090</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab (MEDI4736) will be administered by IV infusion following MEDI9090</description>
    <arm_group_label>MEDI9090</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects

          -  18 years and older

          -  Must have histologic documentation of advanced solid tumors

          -  Must have received and have progressed, are refractory or, intolerant to standard
             therapy and must not have a curative therapy option

        Exclusion Criteria:

          -  Concurrent enrollment in another clinical study

          -  Prior participation in clinical studies that include durvalumab alone or in
             combination

          -  Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MedImmune LLC</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>September 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>MEDI9090</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>Durvalumab</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
